CIK 0001359931
- Non-accelerated filer
- Smaller reporting company
Protara Therapeutics, Inc.
Sign in to watch- Ticker
- TARA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 204580525
- Phone
- +1 646-844-0337
- Business address
- 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK, NY, 10010
- Former names
- Protara Therapeutics, Inc., ArTara Therapeutics, Inc., PROTEON THERAPEUTICS INC
- 4 Grant or award Chf Scientific Operations Off acquired 14,100 shares (grant or award)
- 4 Grant or award CEO and President acquired 42,300 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 14,100 shares (grant or award)
- 4 Open-market buy 10% owner bought 11,591 shares at an average $6.60 ($76,498)
- 4 Open-market buy 10% owner bought 38,000 shares at an average $6.53 ($248,293)
- 4 Open-market buy 10% owner bought 703 shares at $6.49 ($4,562)
- 4 Open-market buy 10% owner bought 10,353 shares at an average $6.46 ($66,899)
- 4 Open-market buy 10% owner bought 24,324 shares at an average $6.98 ($169,774)
- 4 Open-market buy 10% owner bought 6,557 shares at $6.50 ($42,621)
- 4 Open-market buy Chief Medical Officer bought 9,893 shares at an average $10.10 ($99,968)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3/A Insider 3/A
Page 8 of 20 · 382 filings